TrialEuropean journal of haematology2025

Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease.

Laurie DeBonnett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.